Egg white-derived ACE-inhibitory peptides encapsulated in β-glucan-coated liposomes achieved superior blood pressure reduction in hypertensive rats by surviving digestion and targeting specific gut immune cells for enhanced absorption.
Superior to free peptides and uncoated liposomesβ-glucan-functionalized liposomes carrying ACE-inhibitory peptides outperformed both free peptides and standard liposomes in reducing blood pressure in hypertensive rats, demonstrating the value of targeted gut delivery.
What the researchers found
Two egg white-derived ACE-inhibitory peptides (RADHPFL and YAEERYPIL) were encapsulated into liposomes using a controlled microfluidic self-assembly process. β-Glucan was grafted onto the liposomal surface to target intestinal M cells via the Dectin-1 receptor.
Encapsulation significantly improved gastrointestinal stability of the peptides and preserved their ACE inhibitory activity compared to free peptides.
In spontaneously hypertensive rats (SHR), both single-dose and continuous administration of the β-glucan-functionalized liposomes produced superior antihypertensive effects compared to both free peptides and unmodified liposomes. The blood pressure reduction was mediated through modulation of the renin-angiotensin system, improved renal and cardiac function, and amelioration of endothelial dysfunction.
Why it matters
Bioactive peptides from food are an attractive alternative to pharmaceutical blood pressure drugs, but their destruction during digestion has been a major barrier. This study demonstrates that smart delivery technology — using natural materials like β-glucan to target specific gut absorption pathways — can overcome this barrier and deliver meaningful blood pressure reduction. This bridges the gap between food science and drug delivery, potentially enabling functional foods that actually work.
How the study worked
The researchers used microfluidic self-assembly to create liposomes (from lecithin, cholesterol, and DSPE-β-glucan) encapsulating two ACE-inhibitory peptides derived from egg white proteins. Gastrointestinal stability was tested in vitro using simulated digestion. M cell targeting was assessed through Dectin-1 receptor interactions and Peyer's patch uptake studies. Antihypertensive efficacy was tested in spontaneously hypertensive rats using both single-dose and continuous administration protocols, measuring blood pressure along with markers of renin-angiotensin system activity, kidney function, cardiac function, and endothelial health.
What this study cannot tell us
This is an animal study in spontaneously hypertensive rats, a model that may not perfectly represent human hypertension. The complexity of the delivery system (microfluidic assembly, specialized lipid components) may make large-scale manufacturing challenging and costly. Specific blood pressure values and degree of reduction are not reported in the abstract. Long-term safety of chronic liposome ingestion is not addressed. The peptides are derived from egg white, which may be problematic for people with egg allergies. Human bioavailability and efficacy remain to be demonstrated.
How to read the evidence
This is a preclinical study with a well-designed progression from in vitro characterization to in vivo efficacy in a disease model. The use of spontaneously hypertensive rats (a validated model) and multiple administration protocols strengthens the evidence, but human translation remains unproven.
When this study was published
Published in 2025, this is a very recent study at the cutting edge of peptide delivery technology and functional food development.
The bigger picture
The nutraceutical and functional food industries are growing rapidly, but a persistent criticism is that bioactive ingredients often can't survive digestion in meaningful amounts. Targeted nanodelivery systems like the one described here could validate the concept of food-as-medicine for specific conditions like hypertension. The use of β-glucan — itself a recognized health-promoting compound — as a targeting ligand is elegant because it adds its own health benefits while solving the delivery problem.
Questions still open
- Can this β-glucan-liposome delivery system be scaled up cost-effectively for commercial food or supplement products?
- Would the blood pressure reduction in humans be clinically meaningful compared to standard ACE inhibitor medications?
- Could this M cell-targeting approach be used to deliver other bioactive peptides for conditions beyond hypertension?
Common questions
What are M cells and why target them for peptide delivery?
Could egg white peptides replace blood pressure medication?
Read the original research
β-Glucan-Modified Liposomes for Microfold Cell-Targeted Oral Delivery of Food-Derived Angiotensin I-Converting Enzyme Inhibitory Peptides Using Microfluidics.
Journal of agricultural and food chemistry, 73(42), 26733-26749
Citation
Liu, Meijun; Qiao, Fengzhi; Wang, Shaolei; Ding, Wenhao; Xuan, Shichao; De Souza, Cristabelle; Asif Javaid, Muhammad; Zhang, Zhe; Yi, Huaxi; Zhang, Lanwei; Lin, Kai. (2025). β-Glucan-Modified Liposomes for Microfold Cell-Targeted Oral Delivery of Food-Derived Angiotensin I-Converting Enzyme Inhibitory Peptides Using Microfluidics.. Journal of agricultural and food chemistry, 73(42), 26733-26749. https://doi.org/10.1021/acs.jafc.5c08015